Germ-Cell Tumors
Follow-up advised for 2 years after first-line treatment of germ-cell tumors
Published in Clinical Oncology Week, February 27th, 2006
"We performed a retrospective analysis of first relapses after cisplatin-based chemotherapy in patients with advanced germ-cell tumors, in order to better define the appropriate follow-up. These patients were treated between 1986 and 1998 in 2 institutions. They were either followed after first-line chemotherapy at the same center or referred for relapse," scientists writing in the journal European Urology reported.
"Ninety-six patients relapsed (17.5% of the total number of patients treated in the same time period)....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Adenomatous Polyposis
Pancreas-sparing duodenectomy found effective in treating familial adenomatous polyposis - Breast Cancer
Local cancer recurrence minimized with breast conserving therapy - Cancer Therapy
No evidence of gemcitabine accumulation during weekly administration detected - Rectal Cancer
Tumor-related factors were predictors of oncological outcome for rectal cancer - Retinoblastoma
More aggressive bone marrow screening in retinoblastoma patients not recommended - Acute Myeloid Leukemia
Impaired C/EBP alpha function contributes directly to AML development - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
